Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

5.525 -0.025 (-0.45%)
Streaming Delayed Price Updated: 2:07 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relief Therapeutics Hldg Ag

< Previous 1 2 3 4 5 6 7 Next >
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
Via ACCESSWIRE
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
Via ACCESSWIRE
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation
Via ACCESSWIRE
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Via ACCESSWIRE
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)
Via ACCESSWIRE
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Via ACCESSWIRE
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
GENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ")... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc.... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 4 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk
GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
Via Benzinga
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil
GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / June 17, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), announced today that it has filed Amendment No. 3 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001
GENEVA, SWITZERLAND / ACCESSWIRE / June 8, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
GENEVA, SWITZERLAND / ACCESSWIRE / June 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients... 
From Relief Therapeutics Holdings AG
Via AccessWire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients
GENEVA, SWITZERLAND / ACCESSWIRE / May 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics Expands U.S. Commercial Team
Tracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, RespectivelySeasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare... 
From Relief Therapeutics Holdings AG
Via AccessWire
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
GENEVA, SWITZERLAND / ACCESSWIRE / May 11, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 2 to its Registration... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Relief Therapeutics to Participate in Industry and Investor Conferences in May
GENEVA, SWITZERLAND / ACCESSWIRE / May 9, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY)... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures Product Safety
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036 GENEVA, SWITZERLAND / ACCESSWIRE / April... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.